Manifaxine
Jump to navigation
Jump to search
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H15F2NO2 |
| Molar mass | 243.249 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites[citation needed] of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.
See also[edit]
References[edit]
- ^ DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, et al. (August 2002). "GW320659 for the treatment of attention-deficit/hyperactivity disorder in children". Journal of the American Academy of Child and Adolescent Psychiatry. 41 (8): 914–20. PMID 12162627.
- ^ Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, et al. (December 2005). "Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects". Pharmacogenetics and Genomics. 15 (12): 883–9. PMID 16272960.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
